• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

2 Cannabinoid Biotech Companies Added to NASDAQ Biotechnology Index

December 11, 2017


This past Friday, Nasdaq (NASDAQ:NDAQ) announced the results of the annual re-ranking of the NASDAQ Biotechnology Index, which will become effective prior to market open on Monday, December 18, 2017.


While there were 54 biotech companies being added to the index, and another 15 companies being removed, what caught our attention was the fact that two of the companies being added have cannabinoid-related drugs in their pipelines. 


This is a big deal given how many dollars worth of assets are tied to these indices. For instance, the iShares NASDAQ Biotechnology ETF (NASDAQ:IBB) has over $9.5 billion in assets under management.


2 Cannabinoid Biotech Companies Added



Cara Therapeutics, Inc. (NASDAQ:CARA)


Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus.


Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP)


Corbus Pharmaceuticals Holdings is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.




For more cannabinoid-related biotechnology companies, check out our databases here. To stay up to date with important developments in the cannabis industry, be sure to subscribe to one or more of our free email newsletters. Also, connect with The Daily Marijuana Observer on Facebook, Twitter, StockTwits and Instagram!



Please reload

Please reload

Please reload


© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.